AI model aims to predict breast cancer therapy success

NCT ID NCT07671690

Not yet recruiting Diagnosis Sponsor: Yunnan Cancer Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will develop and test an AI model that combines MRI, ultrasound, digital pathology, and patient data to predict how well breast cancer responds to neoadjuvant therapy. Researchers will analyze data from 1,800 participants across multiple centers. The goal is to help doctors identify patients who may benefit from more or less aggressive treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: multimodal deep learning model (MRI, ultrasound, digital pathology, clinical data)
What this could lead to: If successful, this could help doctors personalize breast cancer treatment by predicting which patients will respond well to neoadjuvant therapy, potentially reducing unnecessary side effects.
What could go wrong: This is an early-stage model validation study, not a treatment trial. The model may not be accurate enough for routine use, and results may not apply to all breast cancer patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast carcinoma breast neoplasm invasive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CARCINOMA

More trials for these conditions

Other studies related to the condition(s) this trial covers.